The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation

Citation
M. Frick et al., The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation, EUR HEART J, 21(14), 2000, pp. 1177-1185
Citations number
34
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
EUROPEAN HEART JOURNAL
ISSN journal
0195668X → ACNP
Volume
21
Issue
14
Year of publication
2000
Pages
1177 - 1185
Database
ISI
SICI code
0195-668X(200007)21:14<1177:TEOOMA>2.0.ZU;2-V
Abstract
Aims To determine whether magnesium given orally decreases the recurrence r ate of atrial fibrillation after elective direct current cardioversion of p ersistent atrial fibrillation. Methods and Results Consecutive outpatients were randomized to treatment wi th oral magnesium (10.3 mmol) or placebo twice daily in a double-blind fash ion. Two groups were studied; magnesium study: 170 patients with atrial fib rillation persistent for >1 month, scheduled for their first direct current cardioversion. No concomitant antiarrhythmic drugs of class I or III were allowed. Sotalol and magnesium study: 131 patients with recurrence of persi stent atrial fibrillation after previous direct current cardioversion, or a history of paroxysmal atrial fibrillation, treated with sotalol. Patients were followed until recurrence of atrial fibrillation or for at least 6 mon ths. Magnesium study: at cardioversion 67 of 85 (79%) in the placebo group and 64 of 85 (75%) in the magnesium group had converted to sinus rhythm. At the end of the study, with a follow-up of 6 to 42 months, 15% of patients in the placebo group and 19% of patients in the magnesium group remained in sinus rhythm (Log rank test: P=0.37). Sotalol and magnesium study: pharmac ological conversion to sinus rhythm, after oral treatment, was achieved in 34 of 131 (26%) patients. Sinus rhythm. with or without cardioversion, was restored in 89% and 85% of the patients in the placebo and magnesium groups , respectively. At the end of the study, with a follow-up of 6 to 42 months , 37% of patients in the placebo group and 30% of patients in the magnesium group remained in sinus rhythm (Log rank test: P=0.64). Conclusion In patients with persistent atrial fibrillation, oral treatment with magnesium alone or as an adjuvant to sotalol, does not influence the r ecurrence rate of atrial fibrillation after elective cardioversion. (Eu Hea rt J 2000; 21: 1177-1185) (C) 2000 The European Society of Cardiology.